NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most ...

Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been recognized for its potentially game-changing approach to immune-mod • Findings support the ...

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. IO Biotech ...

IO Biotech’s proprietary T-win ® platform is designed to selectively modulate TGF-β activity rather than fully inhibit it, targeting both tumor cells and key immune-suppressive cells within ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

One of the posters will share insights, using non-clinical models, related to IO Biotech’s lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in advanced ...

An expert look at planning for a biotech job interview ... they are strengthening and adding staff to product development, manufacturing, regulatory and quality assurance functions, as well ...

One of the posters will share insights, using non-clinical models, related to IO Biotech’s lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in ...